164 related articles for article (PubMed ID: 37607946)
1. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal.
Luo M; Wang X; Wu S; Yang C; Su Q; Huang L; Fu K; An S; Xie F; To KKW; Wang F; Fu L
Signal Transduct Target Ther; 2023 Aug; 8(1):312. PubMed ID: 37607946
[TBL] [Abstract][Full Text] [Related]
2. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.
Lin H; Kryczek I; Li S; Green MD; Ali A; Hamasha R; Wei S; Vatan L; Szeliga W; Grove S; Li X; Li J; Wang W; Yan Y; Choi JE; Li G; Bian Y; Xu Y; Zhou J; Yu J; Xia H; Wang W; Alva A; Chinnaiyan AM; Cieslik M; Zou W
Cancer Cell; 2021 Apr; 39(4):480-493.e6. PubMed ID: 33513345
[TBL] [Abstract][Full Text] [Related]
3. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
[TBL] [Abstract][Full Text] [Related]
4. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
5. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
Front Immunol; 2022; 13():944286. PubMed ID: 36591255
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8
Wang R; Liu H; He P; An D; Guo X; Zhang X; Feng M
Front Immunol; 2022; 13():947756. PubMed ID: 36003387
[TBL] [Abstract][Full Text] [Related]
7. TRIB3 reduces CD8
Shang S; Yang YW; Chen F; Yu L; Shen SH; Li K; Cui B; Lv XX; Zhang C; Yang C; Liu J; Yu JJ; Zhang XW; Li PP; Zhu ST; Zhang HZ; Hua F
Sci Transl Med; 2022 Jan; 14(626):eabf0992. PubMed ID: 34985967
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.
Li YY; Wang XY; Li Y; Wang XM; Liao J; Wang YZ; Hong H; Yi W; Chen J
Cell Oncol (Dordr); 2023 Jun; 46(3):777-791. PubMed ID: 36920728
[TBL] [Abstract][Full Text] [Related]
9. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.
Hwang WC; Song D; Lee H; Oh C; Lim SH; Bae HJ; Kim ND; Han G; Min DS
Exp Mol Med; 2022 Sep; 54(9):1563-1576. PubMed ID: 36131027
[TBL] [Abstract][Full Text] [Related]
11. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
12. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
13. m
Wang A; Sun Y; Wang X; Yan Z; Wang D; Zeng L; Lu Q
Aging (Albany NY); 2023 Aug; 15(16):8444-8457. PubMed ID: 37647025
[TBL] [Abstract][Full Text] [Related]
14. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
15. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
Front Immunol; 2022; 13():965492. PubMed ID: 36389685
[TBL] [Abstract][Full Text] [Related]
16. STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop.
Ren Z; Xu Z; Chang X; Liu J; Xiao W
Pharmacol Res; 2024 May; 204():107218. PubMed ID: 38768671
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.
Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
Elife; 2023 Feb; 12():. PubMed ID: 36779699
[TBL] [Abstract][Full Text] [Related]
18. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.
Zhai J; Chen H; Wong CC; Peng Y; Gou H; Zhang J; Pan Y; Chen D; Lin Y; Wang S; Kang W; To KF; Chen Z; Nie Y; He HH; Sung JJ; Yu J
Gastroenterology; 2023 Aug; 165(2):445-462. PubMed ID: 37169182
[TBL] [Abstract][Full Text] [Related]
19. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
[TBL] [Abstract][Full Text] [Related]
20. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]